ENDO 2018

Chicago, IL US

Thank you for attending ENDO 2018 on March 17-20, 2018.  After you complete a short evaluation, you can obtain your Certificate of Attendance, CME Certificate, as well as claim American Board of Pediatric MOC and American Board of Internal Medicine MOC credits. Click the Start button in the Start tab to begin your ENDO 2018 evaluation.

In compliance with Accreditation Council for Continuing Medical Education policy and procedures, the Endocrine Society will be unable to accept MOC credit submissions after December 31, 2018.  Please plan to claim your credits accordingly.

Learning Objectives

Sessions at ENDO cover a full spectrum of research and clinical topics in endocrinology, including diabetes, obesity, lipid disorders, reproduction and infertility, osteoporosis, thyroid disease, growth hormone disorders, pituitary tumors, adrenal insufficiency, and topics therein. Upon completion of this educational activity, attendees will be able to (or better able to):

  • Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia, as well as adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
  • Discuss state-of-the-art research in endocrinology
  • Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae
  • Apply updated knowledge and clinical skills in improving patient care
  • Construct new research questions based on updated scientific and clinical advances in endocrinology-related disciplines

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Endocrine Disruptors
Quality Improvement and Healthcare Delivery
General Endocrinology
Intercellular Signaling and Gene Regulation
Hormone Abuse
Growth Disorders
Health Disparities
Hormones and Cancer
Men’s Health
Neuroendocrinology and Pituitary
Nuclear Receptors and Steroid Hormones
Pediatric Endocrinology
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Course opens: 
Course expires: 
McCormick Place West
2301 S King Dr
Chicago, IL 60616
United States


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Annual Meeting Steering Committee.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

To view disclosure information for all ENDO presenters, please view the full schedule. Within each session abstract and session description, speaker disclosure is presented.


Guillaume Assié, MD, PhD
Co-investigator (Ipsen, Novartis); Invited speaker (Novartis)

Felix Beuschlein, MD
Invited speaker: Ipsen, HRA Pharmaceuticals

Francesco S. Celi, MD
Advisory Board Member, LioTriDev; Consultant, Titan Pharmaceuticals

Lisa S. Chow, MD
Grantee, Eli Lilly

Samuel Dagogo-Jack, MD, MBBS (Clinical Science Chair)
Principal Investigator/Co-investigator for Clinical Trials Contracts to University of Tennessee from AstraZeneca, Novo Nordisk, Boehringer Ingelheim; Consultant/Advisory Board; Amgen, Merck, Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janacare, Janssen, Perle Bioscience, Response Scientific, Inc.; Stock/Warrants:Dance Pharma, Janacare.

David A. D'Alessio, MD
Consultant, Lilly, Janssen, Intarcia, Merck, Novo Nordisk; Grant Recipient, Merck

Scott M. Dehm, PhD
Consultant, Janssen Research and Development LLC

Matthew T. Drake
Advisory Board Member, ABIM, Endocrinology, Diabetes and Metabolism; Self-Assessment Committee Member, US FDA Bone, Reproductive, Urologic Drugs; Scientific Advisory Board Member, Amgen, Soft Bones Foundation, Rare Bone Disease Alliance; Medical Advisory Board Member, Ultragenyx

Maralyn R. Druce, MA, MBBS, FRCP, PhD, MMed, SFHEA
Advisory Board Member, Ipsen; Medical Advisory Board Member, AMEND Charity

Robert Eckel, MD
Scientific Consultant, Sanofi aventis, Regeneron Pharmaceuticals; Scientific Advisor, Novo Nordisk

Richard A. Feelders, MD, PhD
Grant recipient, Novartis, Ipsen

Megan R. Haymart, MD
Grantee, AHRQ

Anders Juul, MD, PHD, DMSC
Invited Speaker/Speakers Bureau, Novo Nordisk, Pfizer, Ferring, Merck, Bayer; Grant Recipient (Department), Novo Nordisk; Sponsor and Grant Recipient (Department), NESGAS. Ferring Pharmaceuticals

Lawrence S. Kirschner, MD, PhD
Advisory Board Member, Corcept Therapeutics

Joshua P. Klopper, MD
Member of Advisory Council, ThyCa; Speaker, Medical Education Resources

Ana Luiza Maia, MD, PhD
Speaker’s Bureau and Consultant, PI multicentric studies, AstraZeneca, Sanofi; PI multicentric studies, GlaxoSmithKline Brasil (spouse). Advisor, Reviewer and Grantee,  CNPq (Brazilian Funding Agency), AIRC (Italian)

John David Charles Newell-Price, MA, PhD, FRCP (AMSC Chair)
Trustee, The Pituitary Foundation (Patient support charity); Advisory Board Member, Novartis, Ipsen, HRA Pharma

Nicola C. Partridge, PhD
Consultant and Research Contract, Orthofix, Inc.

Sally Radovick, MD
Consultant, CVS Caremark

Darleen Sandoval, PhD
Research Funding, Novo Nordisk Sanofi, Ethicon; Invited Speaker, Novo Nordisk

Adrian V. Vella, MD, FRCP
Principal Investigator, Novo Nordisk, Obesity Society; Investigator, XOMA; Advisory Board Member, VTV Therapeutics

The following committee members reported no relevant financial relationships:

Cynthia Andoniadou, PhD; Kristy A. Brown, PhD (Basic Science Chair); Kerry L. Burnstein, PhD; Mark S. Cooper, BM, BCH, PhD, FRCP, FRACP; Ann Danoff, MD (Physician-in-Practice Chair); Carol F. Elias, PhD; Larry A. Fox, MD; Jonna M. Frasor, PhD; Inga Harbuz-Miller, MD; Terence Hebert, BSc, MSc, PhD; Peter Kopp, MD; Stavroula Kousteni, PhD; Yogeshwar Makanji, PhD; Bruce Murphy, PhD; Nalini Shah, DM; Stephanie B. Seminara, MD; Bulent O. Yildiz, MD; Morag J. Young, PhD.

The Endocrine Society staff associated with the development of this program reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.


The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information be disclosed to the learners. Uses of some pharmaceutical agents, medical devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the United States Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before prescribing or recommending any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


The Endocrine Society is proud to partner with industry to advance excellence and promote scientific discovery, medical practice and human health.:

Abbott Diabetes Care Inc.; Aegerion; Amarin Pharma Inc.; Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC; Corcept Therapeutics Incorporated; Dexcom, Inc.; Ethicon Endo-Surgery, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Noven Pharmaceuticals, Inc.; Novo Nordisk Inc.; Pfizer, Inc.; Radius Health, Inc.; SANDOZ, a Novartis Company; Shire; The Leona M. and Harry B. Helmsley Charitable Trust; Ultragenyx Pharmaceutical Inc

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 28.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC):

By attending ENDO 2018, you are eligible to earn a maximum of 28.5 American Board of Internal Medicine (ABIM) Medical Knowledge MOC points. American Board of Pediatrics (ABP) diplomates can earn 20 ABP Part 2 MOC points.

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM) or American Board of Pediatrics (ABP), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers:

    Your ABP Number: [current-user:profile-profile:field-number-abp]*

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABP or ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

  3. To calculate your credits:

    Use the quick credit guide below or track your session attendance via the Daily Schedule (click here for instructions), Program Planner, or the ENDO 2018 App.

    The maximum number of credits per day:


    Sat 3/17


    Sun 3/18


    Mon 3/19


    Tue 3/20 


    Maximum Credits






    Quick guide by session type

    Session Type

    Typical Credits per Session Type

    Symposium (S)
    Oral Abstracts (OR)


    Plenary (PL)
    Clinical Practice Guideline (CPG)
    Master Clinician (MC)

    Knockout Rounds (KO)
    Career Development Workshops (CDW)



    Meet-The-Professor (M)
    Meet-The-Program-Director (MPD)
    Clark T. Sawin History of Endocrinology Lecture  (CTS)
    Endocrine "Year In" (YI)



    Select other sessions, as indicated
















Pre-Conference and/or Ancillary Sessions:

If you attended any additional pre-conference and/or ancillary sessions, you will need to complete a separate evaluation form. You will be sent the link and/or will see the forms in your account pending activities list.

Need your transcript?

Use the bookmarking function on the Meetings App, which allows you to identify your sessions attended and receive a meeting transcript via e-mail. You can bookmark any session simply by clicking on the Star icon next to the title—including overlapping ones, so be sure to mark only those you would like to be reflected on the transcript. At any time, the bookmarked session transcript can be requested via e-mail through the "Email My Event Activity Summary" button at the bottom of the Settings menu (Settings icon looks like a gear on the app homepage) in the Meetings App.

Click "Start" to:

  • Provide ENDO2018 Feedback
  • Obtain Certificate of Attendance and/or Participation
  • Claim up to 28.50 ABIM MOC points
  • Claim up to 20 ABP MOC Part 2 points
  • Claim up to 28.50 CME credits